In 2007, Allergan, the creator of LATISSE®, enlisted a team of 16
renowned doctors, including dermatologists, ophthalmologists and plastic surgeons
from all over the country, to study the safety and efficacy of what would eventually
become LATISSE®. In addition to these Clinical Investigators, many
doctors also served as Advisors for LATISSE® solution. The following
professionals are featured to give you a better understanding of their experiences
with the product.
EXPLORE THE DOCTORS' GALLERY.
Click through the Gallery to hear what various doctors have to say about LATISSE®.
AN INSIDE LOOK AT OUR CLINICAL TRIAL.
The LATISSE® clinical trial was conducted at 16 sites across the
country and lasted over a period of four months. There were 278 participants involved,
including women and men of various ages (22 — 78), backgrounds and eye colors.
These participants were separated into two groups: one which tested LATISSE®
solution and the other which tested a vehicle (or placebo) which was LATISSE®
without its active ingredient. Neither the patients nor the Clinical Investigators
knew which group received what treatment, a common practice designed to ensure that
results are evaluated without any bias.
THE RESULTS THAT LED TO FDA APPROVAL.
Throughout the course of the 16–week treatments, each participant was photographed
and evaluated at four–week intervals (week 0 — week 16) for differences
in their overall lash prominence, including elements of length, thickness and fullness.
By week 16, the results showed that LATISSE® solution was effective
for 78% of those participating (vs. 18% for the vehicle group). The most common
side effects after using LATISSE® solution were itchy eyes and/or
eye redness, which were reported in about 4% of clinical trial participants.
For more information on safety, please see the Safety section on this website, as
well as the Important Safety Information below.